| 88434-6 |
International Physical Activity Questionnaire telephone long form |
- |
^Patient |
Pt |
- |
IPAQ |
|
ACTIVE |
International Physical Activity Questionnaire telephone long form [IPAQ] |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.IPAQ |
|
88434-6 |
|
IPAQ |
|
|
Order |
|
|
|
0 |
|
|
|
|
|
|
Activ; Activity; Actvty; Exercise; IPAQ Tele Long Form; Movements; Pan; Panel; Panl; Patient Telephone; Pnl; Point in time; Random; Survey |
2.64 |
2.64 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 88435-3 |
Cardiac compression start time |
ClockTime |
^Patient |
Pt |
Qn |
|
|
ACTIVE |
Cardiac compression start time |
|
MIN |
DefinitionDescription |
|
|
Clock time |
|
|
|
|
|
|
CARD.PROC |
|
88435-3 |
|
|
|
|
Observation |
|
|
|
0 |
Cardiac comp start time Clock time |
|
|
|
|
|
CARD.PROC; Cardiac comp start time; Cardio; Cardiology; Clock time; Heart Disease; Point in time; QNT; Quan; Quant; Quantitative; Random; Started |
2.7 |
2.64 |
|
|
|
|
|
|
|
{clock_time} |
|
|
|
0 |
| 88436-1 |
Patient counseling information |
- |
^FDA package insert |
- |
Nar |
|
|
ACTIVE |
FDA package insert Patient counseling information |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOC.REF |
|
88436-1 |
|
|
|
|
|
|
|
|
0 |
FDA insert Patient counseling inform |
|
|
|
|
|
DOCUMENT.REF; FDA insert; Narrative; Report; SPL; Structured Product Labelling |
2.64 |
2.64 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 88437-9 |
How supplied & storage & handling section |
- |
^FDA package insert |
- |
Nar |
|
|
ACTIVE |
FDA package insert How supplied and storage and handling section |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOC.REF |
|
88437-9 |
|
|
|
|
|
|
|
|
0 |
FDA insert how suppl + stor + hand sect |
|
|
|
|
|
DOCUMENT.REF; FDA insert; how suppl + stor + hand sect; Narrative; Report; SPL; Structured Product Labelling |
2.64 |
2.64 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 88438-7 |
Cardiopulmonary resuscitation start time |
ClockTime |
^Patient |
Pt |
Qn |
|
|
ACTIVE |
CPR start time |
|
MIN |
DefinitionDescription |
|
|
Clock time |
|
|
|
|
|
|
CARD.PROC |
|
88438-7 |
|
|
|
|
Observation |
|
|
|
0 |
CPR start time Clock time |
|
|
|
|
|
CARD.PROC; Cardio; Cardiology; Clock time; CPR; CPR start time; Heart Disease; Point in time; QNT; Quan; Quant; Quantitative; Random; Started |
2.7 |
2.64 |
|
|
|
|
|
|
|
{clock_time} |
|
|
|
0 |
| 88439-5 |
Hydrogen/Expired gas^10M post dose fructose PO |
VFr |
Exhl gas |
Pt |
Qn |
|
|
ACTIVE |
Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --10M post dose fructose PO |
|
ADD |
DefinitionDescription |
|
|
ppm |
|
|
|
|
|
|
CHAL |
|
88439-5 |
|
|
|
|
Both |
|
|
|
0 |
Breath H2 10M p fruct PO |
|
|
|
|
|
10M p fruct PO; After; Breath; CHEMISTRY.CHALLENGE TESTING; ExG; Exhaled gas; Exhaled gas (=breath); Gases; H2; Hyd; Levulose; p dose; Percent; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Revulose; Volfr; Volume fraction |
2.64 |
2.64 |
|
|
|
|
|
|
|
[ppm] |
|
|
|
0 |
| 8844-3 |
Oxygen saturation |
MFr |
Heart.atrium.right.mid |
Pt |
Qn |
|
|
ACTIVE |
Mid right atrium Oxygen saturation |
|
MIN |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
HEMODYN.MOLEC |
|
8844-3 |
|
|
|
|
|
|
|
|
0 |
SaO2 % RA.mid |
|
|
|
|
|
Atrial; Cardiac; Cardio; Cardiology; Heart Disease; Hemodynamics; HEMODYNAMICS.MOLEC; Hrt; Lung; Mass Fraction; O2; Percent; Point in time; Pulmonary; Pulmonology; QNT; Quan; Quant; Quantitative; R; RA; RA.mid; Random; Respiratory; RT; SaO2; SAT; Satn; SO2; tO2 |
2.4 |
1.0h(3) |
|
|
|
|
|
|
|
% |
|
|
|
0 |
| 88440-3 |
Hydrogen/Expired gas^10M post dose lactose PO |
VFr |
Exhl gas |
Pt |
Qn |
|
|
ACTIVE |
Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --10M post dose lactose PO |
|
ADD |
DefinitionDescription |
|
|
ppm |
|
|
|
|
|
|
CHAL |
|
88440-3 |
|
|
|
|
Both |
|
|
|
0 |
Breath H2 10M p lact PO |
|
|
|
|
|
10M p lact PO; After; Breath; CHEMISTRY.CHALLENGE TESTING; ExG; Exhaled gas; Exhaled gas (=breath); Gases; Gastro; Gastroenterology; GI; H2; Hyd; LTT; p dose; Percent; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Volfr; Volume fraction |
2.64 |
2.64 |
|
|
|
|
|
|
|
[ppm] |
|
|
|
0 |
| 88441-1 |
Hydrogen/Expired gas^20M post dose fructose PO |
VFr |
Exhl gas |
Pt |
Qn |
|
|
ACTIVE |
Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --20M post dose fructose PO |
|
ADD |
DefinitionDescription |
|
|
ppm |
|
|
|
|
|
|
CHAL |
|
88441-1 |
|
|
|
|
Both |
|
|
|
0 |
Breath H2 20M p fruct PO |
|
|
|
|
|
20M p fruct PO; After; Breath; CHEMISTRY.CHALLENGE TESTING; ExG; Exhaled gas; Exhaled gas (=breath); Gases; H2; Hyd; Levulose; p dose; Percent; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Revulose; Volfr; Volume fraction |
2.64 |
2.64 |
|
|
|
|
|
|
|
[ppm] |
|
|
|
0 |
| 88442-9 |
Hydrogen/Expired gas^40M post dose lactose PO |
VFr |
Exhl gas |
Pt |
Qn |
|
|
ACTIVE |
Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --40 minutes post dose lactose PO |
|
ADD |
DefinitionDescription |
|
|
ppm |
|
|
|
|
|
|
CHAL |
|
88442-9 |
|
|
|
|
Both |
|
|
|
0 |
Breath H2 40M p Lac PO |
|
|
|
|
|
40M p Lac PO; After; Breath; CHEMISTRY.CHALLENGE TESTING; ExG; Exhaled gas; Exhaled gas (=breath); Gases; Gastro; Gastroenterology; GI; H2; Hyd; LTT; p dose; Percent; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Volfr; Volume fraction |
2.64 |
2.64 |
|
|
|
|
|
|
|
[ppm] |
|
|
|
0 |
| 88443-7 |
Hydrogen/Expired gas^40M post dose fructose PO |
VFr |
Exhl gas |
Pt |
Qn |
|
|
ACTIVE |
Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --40M post dose fructose PO |
|
ADD |
DefinitionDescription |
|
|
ppm |
|
|
|
|
|
|
CHAL |
|
88443-7 |
|
|
|
|
Both |
|
|
|
0 |
Breath H2 40M p fruct PO |
|
|
|
|
|
40M p fruct PO; After; Breath; CHEMISTRY.CHALLENGE TESTING; ExG; Exhaled gas; Exhaled gas (=breath); Gases; H2; Hyd; Levulose; p dose; Percent; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Revulose; Volfr; Volume fraction |
2.64 |
2.64 |
|
|
|
|
|
|
|
[ppm] |
|
|
|
0 |
| 88444-5 |
Hydrogen/Expired gas^50M post dose fructose PO |
VFr |
Exhl gas |
Pt |
Qn |
|
|
ACTIVE |
Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --50M post dose fructose PO |
|
ADD |
DefinitionDescription |
|
|
ppm |
|
|
|
|
|
|
CHAL |
|
88444-5 |
|
|
|
|
Both |
|
|
|
0 |
Breath H2 50M p fruct PO |
|
|
|
|
|
50M p fruct PO; After; Breath; CHEMISTRY.CHALLENGE TESTING; ExG; Exhaled gas; Exhaled gas (=breath); Gases; H2; Hyd; Levulose; p dose; Percent; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Revulose; Volfr; Volume fraction |
2.64 |
2.64 |
|
|
|
|
|
|
|
[ppm] |
|
|
|
0 |
| 88445-2 |
Hydrogen/Expired gas^50M post dose lactose PO |
VFr |
Exhl gas |
Pt |
Qn |
|
|
ACTIVE |
Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --50M post dose lactose PO |
|
ADD |
DefinitionDescription |
|
|
ppm |
|
|
|
|
|
|
CHAL |
|
88445-2 |
|
|
|
|
Both |
|
|
|
0 |
Breath H2 50M p lact PO |
|
|
|
|
|
50M p lact PO; After; Breath; CHEMISTRY.CHALLENGE TESTING; ExG; Exhaled gas; Exhaled gas (=breath); Gases; Gastro; Gastroenterology; GI; H2; Hyd; LTT; p dose; Percent; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Volfr; Volume fraction |
2.64 |
2.64 |
|
|
|
|
|
|
|
[ppm] |
|
|
|
0 |
| 88446-0 |
Hydrogen/Expired gas^20M post dose lactose PO |
VFr |
Exhl gas |
Pt |
Qn |
|
|
ACTIVE |
Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --20 minutes post dose lactose PO |
|
ADD |
DefinitionDescription |
|
|
ppm |
|
|
|
|
|
|
CHAL |
|
88446-0 |
|
|
|
|
Both |
|
|
|
0 |
Breath H2 20M p Lac PO |
|
|
|
|
|
20M p Lac PO; After; Breath; CHEMISTRY.CHALLENGE TESTING; ExG; Exhaled gas; Exhaled gas (=breath); Gases; Gastro; Gastroenterology; GI; H2; Hyd; LTT; p dose; Percent; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Volfr; Volume fraction |
2.64 |
2.64 |
|
|
|
|
|
|
|
[ppm] |
|
|
|
0 |
| 88447-8 |
Liver fibrosis interpretation |
Imp |
Ser |
Pt |
Ord |
|
|
ACTIVE |
Liver fibrosis interpretation in Serum Qualitative |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
88447-8 |
|
|
|
|
Both |
|
|
|
0 |
Liver fibrosis interpretation Ser-Imp |
|
|
|
|
|
Chemistry; Impression; Impression/interpretation of study; Impressions; Interp; Interpret; Interpretation; Interpt; Intrp; Ordinal; Point in time; QL; Qual; Qualitative; Random; Screen; Serum; SR; The Fibro Test |
2.64 |
2.64 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 88448-6 |
Necroinflammatory activity interpretation |
Imp |
Ser |
Pt |
Ord |
|
|
ACTIVE |
Necroinflammatory activity interpretation in Serum Qualitative |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
88448-6 |
|
|
|
|
Both |
|
|
|
0 |
Necroinflammatory activ interp Ser-Imp |
|
|
|
|
|
Acti Test; Activ; Actvty; Chemistry; Impression; Impression/interpretation of study; Impressions; Interp; Interpret; Interpretation; Interpt; Intrp; Movements; Necroinflammatory activ interp; Ordinal; Point in time; QL; Qual; Qualitative; Random; Screen; Serum; SR |
2.64 |
2.64 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 88449-4 |
Coagulation factor IX activity actual/Normal |
RelCCnc |
PPP |
Pt |
Qn |
Chromo |
|
ACTIVE |
Coagulation factor IX activity actual/normal in Platelet poor plasma by Chromogenic method |
|
MIN |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
COAG |
|
88449-4 |
|
Chromo |
|
|
Both |
|
|
|
0 |
Fact IX Act/Nor PPP Chro |
|
|
|
|
|
Act/Nor; Activ; Actvty; Antihemophilic factor B; Christmas factor; Chromogenic assay; Coag; Control; ENZY; Enzymatic assay; Fac; Fact; Fact IX; Factor 9; FIX; Hematology; Heme; Movements; Plas; Plasma thromboplastin component; Platelet poor plasma; Point in time; PTC; QNT; Quan; Quant; Quantitative; Random; RlCCnc; Thrombocyte cofactor II |
2.73 |
2.64 |
|
|
|
|
|
|
|
% |
|
|
|
0 |
| 8845-0 |
Oxygen saturation |
MFr |
Heart.ventricle.left |
Pt |
Qn |
|
|
ACTIVE |
Left ventricular Oxygen saturation |
|
MIN |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
HEMODYN.MOLEC |
|
8845-0 |
|
|
|
|
|
|
|
|
0 |
SaO2 % LV |
|
|
|
|
|
Cardiac; Cardio; Cardiology; Heart Disease; Hemodynamics; HEMODYNAMICS.MOLEC; Hrt; Hrt ventr; L; LT; Lung; LV; Mass fraction; O2; Percent; Point in time; Pulmonary; Pulmonology; QNT; Quan; Quant; Quantitative; Random; Respiratory; SaO2; SAT; Satn; SO2; tO2; Ventricular |
2.73 |
1.0h(3) |
|
|
|
|
|
|
|
% |
|
|
|
0 |
| 88450-2 |
Babesia divergens+MO-1 strain 18S rRNA gene |
PrThr |
Bld |
Pt |
Ord |
Non-probe.amp.tar |
|
ACTIVE |
Babesia divergens+MO-1 strain 18S rRNA gene [Presence] in Blood by NAA with non-probe detection |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
88450-2 |
|
Non-probe.amp.tar |
|
|
Both |
|
|
|
0 |
B div+MO-1 18S rRNA Bld Ql NAA+non-probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; B div+MO-1 18S; B div+MO-1 18S rRNA; B divergens; Babesiosis; Blood; DNA NUCLEIC ACID PROBE; DNA probe; Gen-Probe; i; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; month; NAA+non-probe; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Piroplasmosis; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; rDNA; ribosomal RNA; Screen; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification; WB; Whole blood |
2.64 |
2.64 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 88451-0 |
Babesia duncani 18S rRNA gene |
PrThr |
Bld |
Pt |
Ord |
Non-probe.amp.tar |
|
ACTIVE |
Babesia duncani 18S rRNA gene [Presence] in Blood by NAA with non-probe detection |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
88451-0 |
|
Non-probe.amp.tar |
|
|
Both |
|
|
|
0 |
B duncani 18S rRNA Bld Ql NAA+non-probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; B duncani; B duncani 18S; B duncani 18S rRNA; Babesia WA1; Babesiosis; Blood; DNA NUCLEIC ACID PROBE; DNA probe; Gen-Probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+non-probe; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Piroplasmosis; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; rDNA; ribosomal RNA; Screen; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification; WB; Whole blood |
2.64 |
2.64 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 88452-8 |
Babesia microti 18S rRNA gene |
PrThr |
Bld |
Pt |
Ord |
Non-probe.amp.tar |
|
ACTIVE |
Babesia microti 18S rRNA gene [Presence] in Blood by NAA with non-probe detection |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
88452-8 |
|
Non-probe.amp.tar |
|
|
Both |
|
|
|
0 |
B microti 18S rRNA Bld Ql NAA+non-probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; B microti; B microti 18S; B microti 18S rRNA; Babesiosis; Blood; DNA NUCLEIC ACID PROBE; DNA probe; Gen-Probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+non-probe; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Piroplasmosis; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; rDNA; ribosomal RNA; Screen; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification; WB; Whole blood |
2.64 |
2.64 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 88453-6 |
HIV 1 RNA+Hepatitis C virus RNA+Hepatitis B virus DNA |
PrThr |
Ser/Plas/Bld^Donor |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
HIV 1 RNA+Hepatitis C virus RNA+Hepatitis B virus DNA [Presence] in Serum, Plasma or Blood from Donor by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
88453-6 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
HIV1+HCV+HBV SerPlBld Donr NAA+prb |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; AIDS; Amplif; Amplification; Amplified; Blood; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; Donr; HBV; HCV; Hep; Hep B; Hep B virus; Hep C; Hepatis; Hepatit; Hepatitis C virus; HepB; HIV; HIV 1 RNA+HCV RNA+HBV; HIV 1+HCV RNA+HBV DNA; HIV type 1; HIV type I; HIV1; Human immunodeficiency virus; i; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Pl; PlasBld; Plasma; Plsm; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Ribonucleic acid; Screen; SDA; SerP; SerPl; SerPlas; SerPlBld; Serum; Serum or plasma; Serum, plasma or whole blood; SR; Strand Displacement Amplification; TMA; Transcription mediated amplification; WB; Whole blood |
2.73 |
2.64 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 88454-4 |
Mumps virus Ab.IgG+IgM |
Imp |
CSF |
Pt |
Ord |
IF |
|
ACTIVE |
Mumps virus IgG+IgM Ab [Interpretation] in Cerebral spinal fluid Qualitative by Immunofluorescence |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
88454-4 |
|
IF |
|
|
Both |
|
|
|
0 |
MuV IgG+IgM CSF IF-Imp |
|
|
|
|
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; Cerebral spinal fluid; Cerebrospinal Fl; Epidemic Parotitis; FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immune globulin G; Immune globulin M; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin G; Immunoglobulin M; Impression; Impression/interpretation of study; Impressions; Infectious Disease; InfectiousDisease; Interp; Interpretation; Microbiology; Mumps virus antibody; Mumps virus IgG; Mumps virus IgM; MuV; Neuro; Neurology; Ordinal; Point in time; QL; Qual; Qualitative; Random; Screen; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Time Resolved Fluorescence; TRF |
2.65 |
2.64 |
|
|
|
|
|
|
|
|
|
|
Corrected Class from SERO to MICRO |
0 |
| 88455-1 |
California encephalitis virus Ab.IgG & IgM panel |
- |
Ser |
Pt |
- |
IF |
|
ACTIVE |
California encephalitis virus Ab.IgG and IgM panel - Serum by Immunofluorescence |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.MICRO |
|
88455-1 |
|
IF |
|
|
Order |
|
|
|
0 |
CEV Ab.IgG & IgM panel Ser IF |
|
|
|
|
|
ACIF; Anticomplement Immunofluorescence; CA; Calif; California encephalitis virus Ab; California Encephalitis Virus AB IGG; California Encephalitis Virus AB IGM; CEV; CEV Ab; CEV Ab.IgG & IgM panel; CEV Ab.IgG+IgM; CEV IgG; CEV IgG & IgM; Enc; Enceph; Encephalomyelitis; FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immune globulin G; Immune globulin M; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin G; Immunoglobulin M; Infectious Disease; InfectiousDisease; Microbiology; Pan; PANEL.MICROBIOLOGY; Panl; Pnl; Point in time; Random; Serum; SR; Time Resolved Fluorescence; TRF |
2.65 |
2.64 |
|
Panel |
|
|
|
|
|
|
|
|
Corrected Class from PANEL.SERO to PANEL.MICRO |
0 |
| 88456-9 |
California encephalitis virus Ab.IgG+IgM |
Imp |
Ser |
Pt |
Ord |
IF |
|
ACTIVE |
California encephalitis virus IgG+IgM Ab [Interpretation] in Serum Qualitative by Immunofluorescence |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
88456-9 |
|
IF |
|
|
Both |
|
|
|
0 |
CEV IgG+IgM Ser IF-Imp |
|
|
|
|
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; CA; Calif; California encephalitis virus Ab; California Encephalitis Virus AB IGG; California Encephalitis Virus AB IGM; CEV; CEV Ab; CEV Ab.IgG+IgM; CEV IgG; CEV IgG & IgM; Enc; Enceph; Encephalomyelitis; FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immune globulin G; Immune globulin M; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin G; Immunoglobulin M; Impression; Impression/interpretation of study; Impressions; Infectious Disease; InfectiousDisease; Interp; Interpretation; Microbiology; Ordinal; Point in time; QL; Qual; Qualitative; Random; Screen; Serum; SR; Time Resolved Fluorescence; TRF |
2.65 |
2.64 |
|
|
|
|
|
|
|
|
|
|
Corrected Class from SERO to MICRO |
0 |
